Continuous GLP-1RA Use Reduces MACE Risk Incident use of GLP-1RAs was associated with a lower risk of MACE compared to incident use of sulfonylureas
GLP-1 medications affect everyone differently, so please talk with your own doctor or a qualified healthcare provider about what's right for you before starting, changing, or stopping any treatment
Dosage and Administration Starting doses are typically low to minimize side effects like nausea
Saxenda European Medicines Agency EPAR overview
Conclusion Understanding how medications interact with each other is an important part of staying safe and healthy
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA, Rosenstock J